Modulation of the Kynurenine Pathway: A New Approach for Treating Neurodegeneration.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical concepts without primary human data or systematic review methodology
PubMed 41752903 · doi:10.3390/life16020266
What was done
Narrative review evaluating strategies to modulate the kynurenine pathway of tryptophan metabolism in neurodegenerative diseases, including Parkinson's and Alzheimer's. The authors discussed pharmacological approaches (such as IDO and KMO inhibitors), non-pharmacological interventions (exercise and diet), and combination therapies across preclinical and clinical literature.
What was found
The abstract reports no quantitative results, effect sizes, or study counts. It qualitatively summarizes the biological premise that shifting metabolism away from neurotoxic metabolites (e.g., quinolinic acid) toward neuroprotective products may decrease inflammation, oxidative stress, and neuronal loss.
Why it matters
The paper synthesizes emerging pharmacological and lifestyle targets within tryptophan metabolism for neurodegenerative disease research.
Limits
This is a narrative review containing no original empirical data, quantitative synthesis, or risk-of-bias assessment. Findings summarized in the abstract are largely based on mechanistic and preclinical reasoning.
Cited by
- partial Kynurenic acid and quinolinic acid are neurotoxic serotonin/tryptophan pathway metabolites associated with brain inflammation.